Department of Otorhinolaryngology, Shinshu University School of Medicine, Asahi, Matsumoto, Japan.
PLoS One. 2013 Aug 13;8(8):e71381. doi: 10.1371/journal.pone.0071381. eCollection 2013.
Target exon resequencing using Massively Parallel DNA Sequencing (MPS) is a new powerful strategy to discover causative genes in rare Mendelian disorders such as deafness. We attempted to identify genomic variations responsible for deafness by massive sequencing of the exons of 112 target candidate genes. By the analysis of 216randomly selected Japanese deafness patients (120 early-onset and 96 late-detected), who had already been evaluated for common genes/mutations by Invader assay and of which 48 had already been diagnosed, we efficiently identified causative mutations and/or mutation candidates in 57 genes. Approximately 86.6% (187/216) of the patients had at least one mutation. Of the 187 patients, in 69 the etiology of the hearing loss was completely explained. To determine which genes have the greatest impact on deafness etiology, the number of mutations was counted, showing that those in GJB2 were exceptionally higher, followed by mutations in SLC26A4, USH2A, GPR98, MYO15A, COL4A5 and CDH23. The present data suggested that targeted exon sequencing of selected genes using the MPS technology followed by the appropriate filtering algorithm will be able to identify rare responsible genes including new candidate genes for individual patients with deafness, and improve molecular diagnosis. In addition, using a large number of patients, the present study clarified the molecular epidemiology of deafness in Japanese. GJB2 is the most prevalent causative gene, and the major (commonly found) gene mutations cause 30-40% of deafness while the remainder of hearing loss is the result of various rare genes/mutations that have been difficult to diagnose by the conventional one-by-one approach. In conclusion, target exon resequencing using MPS technology is a suitable method to discover common and rare causative genes for a highly heterogeneous monogenic disease like hearing loss.
使用大规模平行 DNA 测序(MPS)对靶外显子进行重测序是发现罕见孟德尔疾病(如耳聋)致病基因的一种新的强大策略。我们试图通过对 112 个候选靶基因的外显子进行大规模测序,来鉴定导致耳聋的基因组变异。通过对 216 名已通过 Invader 检测评估常见基因/突变的日本耳聋患者(120 名早发性和 96 名迟发性)的随机选择分析,其中 48 名已确诊,我们在 57 个基因中有效地鉴定出了致病突变和/或突变候选基因。大约 86.6%(187/216)的患者至少有一个突变。在 187 名患者中,69 名患者的听力损失病因完全得到解释。为了确定哪些基因对耳聋病因有最大影响,计算了突变数量,结果表明 GJB2 的突变数量异常高,其次是 SLC26A4、USH2A、GPR98、MYO15A、COL4A5 和 CDH23 的突变。本研究数据表明,使用 MPS 技术对选定基因进行靶向外显子测序,然后通过适当的过滤算法,将能够鉴定出包括新候选基因在内的个别耳聋患者的罕见致病基因,从而提高分子诊断水平。此外,通过大量患者,本研究阐明了日本耳聋的分子流行病学。GJB2 是最常见的致病基因,主要(常见)基因突变导致 30-40%的耳聋,而其余听力损失是各种难以通过传统逐一方法诊断的罕见基因/突变的结果。总之,使用 MPS 技术进行靶向外显子重测序是发现高度异质性单基因疾病(如耳聋)常见和罕见致病基因的合适方法。